Understand the hematology partnering landscape using intelligence from 234 real-world collaboration and licensing deals.
Hematology Collaboration and Licensing Deals 2016-2026 provides comprehensive intelligence on 234 partnering deals involving hematology assets, technologies and development programs.
Hematology partnering spans both malignant and non-malignant disorders and encompasses a diverse range of therapeutic approaches, technologies and stages of development. Deal structures reflect the scientific complexity of the field, the increasing use of targeted and advanced therapeutic approaches, and differing development and commercialization strategies across individual indications.
The report brings this activity together in one resource, enabling users to understand who is partnering, which hematology opportunities are attracting interest, how transactions are structured, what financial terms have been disclosed and how dealmaking differs across therapeutic indications, technologies and stages of development.
Rather than simply providing a list of transactions, the report combines market-wide deal analysis with financial benchmarking, leading dealmaker intelligence, detailed transaction records and access to publicly available contract documents where available.
It provides a practical intelligence and benchmarking resource for business development, licensing, search and evaluation, corporate strategy, R&D strategy, competitive intelligence and legal teams involved in hematology partnering.
This provides real-world reference points for internal benchmarking, opportunity assessment, deal preparation and negotiation.
Financial benchmarks are most useful when interpreted alongside the structure and circumstances of comparable transactions rather than as standalone averages, and the report provides the underlying deal intelligence needed to establish that context.
The report analyzes partnering by therapeutic indication and therapeutic target, enabling users to move beyond broad hematology benchmarks and focus on transactions most relevant to a particular program or strategic interest.
Combined with analysis by technology and development stage, this helps users identify more meaningful comparable transactions and prospective partners.
Identify comparable hematology transactions, prospective partners and relevant deal structures.
Search and Evaluation teams
Understand which companies are actively seeking hematology opportunities across relevant indications, technologies and development stages.
Biotechnology Companies Seeking Partners
Identify organizations with demonstrated interest in comparable hematology assets and technologies.
Corporate and R&D Strategy teams
Understand how competitors and prospective partners are building hematology portfolios through external innovation.
Competitive and Market Intelligence teams
Track partnering activity by company, indication, target, development stage and technology to understand evolving strategic priorities.
Legal and Transaction teams
Review publicly available contracts and precedent agreement structures to support transaction preparation and negotiation.
The briefing applies the underlying hematology deal intelligence to the customer's own asset, technology, indication, target or partnering objectives.
Depending on requirements, this can include relevant comparable transactions, prospective partners, competitor activity, development-stage analysis, deal structures, financial benchmarks, royalty analysis, contract insights and other intelligence selected specifically for the client's situation.
Hematology Collaboration and Licensing Deals 2016-2026 provides comprehensive intelligence on 234 partnering deals involving hematology assets, technologies and development programs.
Hematology partnering spans both malignant and non-malignant disorders and encompasses a diverse range of therapeutic approaches, technologies and stages of development. Deal structures reflect the scientific complexity of the field, the increasing use of targeted and advanced therapeutic approaches, and differing development and commercialization strategies across individual indications.
The report brings this activity together in one resource, enabling users to understand who is partnering, which hematology opportunities are attracting interest, how transactions are structured, what financial terms have been disclosed and how dealmaking differs across therapeutic indications, technologies and stages of development.
Rather than simply providing a list of transactions, the report combines market-wide deal analysis with financial benchmarking, leading dealmaker intelligence, detailed transaction records and access to publicly available contract documents where available.
It provides a practical intelligence and benchmarking resource for business development, licensing, search and evaluation, corporate strategy, R&D strategy, competitive intelligence and legal teams involved in hematology partnering.
Understand the hematology partnering landscape
The report analyzes hematology dealmaking from 2016 to 2026, including:
- Trends in hematology partnering by year
- Deal activity by deal type
- Industry sector
- Stage of development at the time of partnering
- Technology type
- Therapeutic indication
- Most active hematology dealmakers
- Leading deals by disclosed value
- How hematology partnering activity is evolving
Benchmark hematology deal financials
Financial terms can vary considerably according to the asset, development stage, technology, rights granted and overall transaction structure.The report provides dedicated analysis of disclosed financial terms, including:
- Headline deal values
- Upfront payments
- Milestone payments
- Royalty rates
This provides real-world reference points for internal benchmarking, opportunity assessment, deal preparation and negotiation.
Financial benchmarks are most useful when interpreted alongside the structure and circumstances of comparable transactions rather than as standalone averages, and the report provides the underlying deal intelligence needed to establish that context.
Identify leading hematology dealmakers and prospective partners
The report identifies the most active companies in hematology partnering and provides transaction histories that enable users to investigate their previous activity.This can help users identify:
- Companies actively seeking hematology opportunities
- Prospective licensing and collaboration partners
- Organizations repeatedly partnering in relevant hematology indications
- Companies active at relevant stages of development
- Dealmakers demonstrating interest in particular technologies or therapeutic approaches
- Competitors pursuing related external innovation strategies
Compare partnering activity across hematology indications and targets
Hematology covers a range of malignant and non-malignant disorders with differing scientific, clinical and commercial dynamics.The report analyzes partnering by therapeutic indication and therapeutic target, enabling users to move beyond broad hematology benchmarks and focus on transactions most relevant to a particular program or strategic interest.
Combined with analysis by technology and development stage, this helps users identify more meaningful comparable transactions and prospective partners.
Understand how hematology agreements are structured
The report includes collaboration, licensing, development, research and other partnering transactions.Depending on the transaction and available disclosure, users can investigate areas including:
- Rights granted and retained
- Research and development responsibilities
- Licensing rights
- Exclusivity
- Geographic rights
- Intellectual property
- Development and regulatory obligations
- Manufacturing and supply responsibilities
- Commercialization rights
- Financial consideration
- Milestones and royalties
- Governance
- Term and termination provisions
Learn from real-world contract documents
Where publicly available, the report provides access to underlying contract documents for selected hematology transactions.These agreements can provide substantially more detail than headline announcements alone, enabling users to examine how companies have documented areas such as:
- Scope of rights
- Development obligations
- Intellectual property
- Exclusivity
- Financial terms
- Milestone triggers
- Royalty provisions
- Commercialization rights
- Termination and other negotiated provisions
Comprehensive hematology deal directory
The report includes a comprehensive directory of 234 hematology collaboration and licensing deals, providing a focused resource for identifying relevant precedent transactions.Deals can be reviewed by:
- Company
- Technology type
- Therapeutic indication or target
- Contract availability
Who should use this report?
Business Development and Licensing teamsIdentify comparable hematology transactions, prospective partners and relevant deal structures.
Search and Evaluation teams
Understand which companies are actively seeking hematology opportunities across relevant indications, technologies and development stages.
Biotechnology Companies Seeking Partners
Identify organizations with demonstrated interest in comparable hematology assets and technologies.
Corporate and R&D Strategy teams
Understand how competitors and prospective partners are building hematology portfolios through external innovation.
Competitive and Market Intelligence teams
Track partnering activity by company, indication, target, development stage and technology to understand evolving strategic priorities.
Legal and Transaction teams
Review publicly available contracts and precedent agreement structures to support transaction preparation and negotiation.
Turn market-wide hematology intelligence into company-specific insight
For qualifying customers, the analyst can also provide a Customized Executive Partnering Briefing alongside the report.The briefing applies the underlying hematology deal intelligence to the customer's own asset, technology, indication, target or partnering objectives.
Depending on requirements, this can include relevant comparable transactions, prospective partners, competitor activity, development-stage analysis, deal structures, financial benchmarks, royalty analysis, contract insights and other intelligence selected specifically for the client's situation.
Table of Contents
Executive SummaryChapter 1 - Introduction
Chapter 2 - Trends in hematology dealmaking
Chapter 3 - Financial deal terms for hematology partnering
Chapter 4 - Leading hematology deals and dealmakers
Chapter 5 - Hematology contract document directory
Chapter 6 - Hematology dealmaking by therapeutic target
Deal directory
Table of figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 2seventy bio
- 3DR Labs
- Abbvie
- ABVC BioPharma
- Acceleron Pharma
- Acrotech Biopharma
- Adaptive Biotechnologies
- AffaMed Therapeutics
- AgeX Therapeutics
- Agilent Technologies
- Agios Pharmaceuticals
- AkaRx
- Akebia Therapeutics
- Albert Einstein College of Medicine
- Alexion Pharmaceuticals
- Alfasigma
- Alivexis
- Alvotech
- ALZpath
- Amag Pharmaceuticals
- American Red Cross
- American Society of Hematology
- Antengene
- Anthos Therapeutics
- Anthropic
- Apellis Pharmaceuticals
- Aplagon
- Aplastic Anemia & MDS International Foundation
- Aptahem
- APT Therapeutics
- Arbor Biotechnologies
- ArcherDX
- Aruvant Sciences
- ASC Therapeutics
- ASKA Pharmaceuticals
- Association for the Advancement of Blood & Biotherapies
- AstraZeneca
- Atomwise
- Audaire Health
- Babson Diagnostics
- Baxalta
- Baxter International
- Bayer
- Bayer Healthcare
- Beam Therapeutics
- Becton Dickinson
- Beijing InnoCare Pharma
- Beth Israel Deaconess Medical Center
- Beyondspring Pharmaceuticals
- Bicycle Therapeutics
- Bill and Melinda Gates Foundation
- BillionToOne
- Bioceros
- BIOCORP
- Biolog-id
- BioMatrix Specialty Pharmacy
- Biomed Elements
- Biomedical Advanced Research and Development Authority
- BioSpring
- Bioverativ
- Blau Pharma
- Blood Centers of America
- Bluebird Bio
- Bluejay Diagnostics
- Boryung Pharmaceutical
- Bristol-Myers Squibb
- Brooklyn ImmunoTherapeutics
- C-Bridge Capital
- Cadila Pharmaceuticals
- Cadrenal Therapeutics
- California Institute for Regenerative Medicine
- Calithera Biosciences
- CAMP4 Therapeutics
- Canadian Blood Services
- Cardiovascular Systems
- Caring Cross
- Celgene
- Cellphire
- Cell Point
- Centogene
- Cerus
- Children's Hospital Boston
- Children's Hospital of Philadelphia
- Children's Hospital Of Wisconsin
- Children's Minnesota
- China Medical System
- Cincinnati Children’s Hospital Medical Center
- City of Hope
- Civica Rx
- CJ Corp
- Clinigen
- Codexis
- Comercializadora BioRenal
- Companhia Energetica Integrada
- ConcertAI
- CRISPR Therapeutics
- CSL Behring
- CSL Plasma
- Curetis
- CytoSorbents
- Daiichi Sankyo
- Danaher
- Daxor
- Defense Health Agency (US)
- Department of Defense
- Department of Health and Human Services
- Dialco Medical
- Diffusion Pharmaceuticals
- Disc Medicine
- Domainex
- Dong-A Pharmaceutical
- Drawbridge Health
- Drogsan Pharmaceuticals
- Duke University
- Eddingpharm
- Editas Medicine
- Eisai
- Emendo Biotherapeutics
- Enable Injections
- Enlaza Therapeutics
- Enzyre
- EpiDestiny
- Ergomed
- Esperion Therapeutics
- European Medicines Agency
- Evive Biotechnology
- Ewopharma
- ExCellThera
- Expression Therapeutics
- ExThera Medical
- Factor Bioscience
- Feinstein Institute for Medical Research
- Fibriant
- Fibrogen
- Foresee Pharmaceuticals
- Forty Seven
- Foundation for Innovative New Diagnostics
- Fresenius Medical Care
- Fulcrum Therapeutics
- GC Pharma
- GE Healthcare
- Genentech
- Genetix Biotherapeutics
- Genevant Sciences
- Genexine
- GenScript ProBio
- GenVec
- German Federal Ministry of Education and Research
- Global Blood Therapeutics
- Golden Meditech
- Greiner Bio-One
- Grifols
- GSK
- Halozyme Therapeutics
- HanAll Pharmaceuticals
- Handok Pharmaceuticals
- Healthcare Royalty Partners
- Hemanext
- Hemex Health
- HemoMinas Foundation
- Hemosonics
- HitGen
- Homology Medicines
- Hong Kong Red Cross Blood Transfusion Service
- Immunome
- Incyte
- Infomed
- Inmagene Biopharmaceuticals
- Innova Vascular
- Institute for Genome Statistics and Bioinformatics
- Institute of Hematology and Blood Transfusion
- Institute of Human Genetics
- Intas Pharmaceuticals
- Intellia Therapeutics
- inviCRO
- Ionis Pharmaceuticals
- Irish Haemophilia Society
- Jasper Therapeutics
- Jazz Pharmaceuticals
- JEIL Pharmaceutical
- Jiangsu Hansoh Pharmaceutical
- Jiangsu Hengrui Medicine
- Jiangsu Hengrui Pharmaceuticals
- Johnson & Johnson
- Kaleido Biosciences
- Kamada
- Kedrion Biopharma
- Keros Therapeutics
- Kiromic Biopharma
- Kissei Pharmaceutical
- Knight Therapeutics
- Kurin
- La Jolla Pharmaceutical
- LaNova Medicines
- Lee's Pharmaceutical
- LogicBio Therapeutics
- Loop Medical
- Lotus Pharmaceuticals
- LUNAC Therapeutics
- MaaT Pharma
- Mabwell Bioscience
- Magenta Therapeutics
- Marathon Medical
- Massachusetts Institute of Technology
- Massive Bio
- Maxcyte
- Mayo Clinic
- MD Anderson Cancer Center
- Medical Technology Enterprise Consortium
- Medice Arzneimittel Pütter
- MedImmune
- Medison Pharma
- Melodia Therapeutics
- Menarini
- MicroHealth
- Minaris Regenerative Medicine
- MindRank AI
- Ministry of Defence
- Molecular Templates
- Nantes University
- National Cancer Institute
- National Center for Advancing Translational Sciences (NCATS)
- National Heart
- Lung and Blood Institute
- National Hemophilia Foundation
- National Institutes of Health
- NCPC GeneTech
- Nencki Institute
- Neogenomics
- Neoletix Biotechnology
- Neurimmune Therapeutics
- New York Blood Center
- Norgine
- Novartis
- Novellus Biopharma
- Novellus Therapeutics
- NovImmune
- Novo Nordisk
- Nurix Therapeutics
- Nxera Pharma
- Oak Hill Bio
- Omeros
- OMRF
- Onconova Therapeutics
- OncoX BioPharma
- Orchard Therapeutics
- Orna Therapeutics
- Oscotec
- Otsuka
- Owkin
- Oxford BioMedica
- Pan American Cancer Treatment Centers
- PathoQuest
- PBM Capital Group
- Pfenex
- Pfizer
- PhaseBio Pharmaceuticals
- PicnicHealth
- Pieris Pharmaceuticals
- PixCell Medical
- Platelet BioGenesis
- Polifarma
- Portola Pharmaceuticals
- Poseida Therapeutics
- Precision BioSciences
- Pregene Biopharma
- Prime Therapeutics
- Prolytix
- Protagonist Therapeutics
- QIAGEN
- Queens University
- Quercis Pharma
- Regen BioPharma
- Regeneron Pharmaceuticals
- Regenesis Biomedical
- ReNAgade Therapeutics
- Resonance Health
- Rigel Pharmaceuticals
- Roche
- Rocket Pharmaceuticals
- Rockwell Medical
- Roivant Sciences
- Romanian National Institute of Infectious Diseases
- Royal College of Surgeons (Ireland)
- RPRD Diagnostics
- Sage Bionetworks
- Samsung Bioepis
- Sandoz
- Sangamo Therapeutics
- Sanguina
- Saudi Pharmaceutical Industries & Medical Appliances Corporation (SPIMACO)
- Science Foundation Ireland
- Seattle Childrens Research Institute
- Selecta Biosciences
- Selexis
- SERB Pharmaceuticals
- Sernova
- Seventh Sense Biosystems
- SFJ Pharmaceuticals
- Shanghai RAAS Blood Products
- Shield Therapeutics
- Shionogi
- Shire Laboratories
- Shire Pharmaceuticals
- Sidero Bioscience
- Siemens Healthineers
- Sigilon Therapeutics
- Similis Bio
- Small Business Innovation Research
- SOPHiA Genetics
- Spark Therapeutics
- SQI Diagnostics
- SRS Life Sciences
- Statera Biopharma
- Strm.Bio
- Sumitomo Dainippon Pharma
- Supernus Pharmaceuticals
- Swedish Orphan Biovitrum
- Swiss Transfusion SRC
- Syna Therapeutics
- Syros Pharmaceuticals
- Sysmex
- Takeda Pharmaceutical
- Terumo Blood and Cell Technologies
- Teva Pharmaceutical Industries
- Therapeutic Solutions International
- Tivic Health Systems
- Trialbee
- TRPharm
- Turgut Ilaclari
- Uniformed Services University of the Health Sciences
- UniQure
- University Medical Center Utrecht
- University of Bonn
- University of Cincinnati
- University of Colorado
- University of Pittsburgh
- University of Texas
- US Army
- US Veterans Administration
- Velesco
- Velico Medical
- Veralox Therapeutics
- VeriSIM Life
- Versiti Blood Research Institute
- Vertex Pharmaceuticals
- Vifor Pharma
- Vigene Biosciences
- Vizient
- Wanbang Biopharmaceuticals
- Wanchunbulin
- Washington University in St Louis
- Werum IT Solutions
- Western New England University
- Xenetic Biosciences
- Zealand University Hospital
- Zenas BioPharma
- Zydus Cadila
Methodology
- The publisher reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
- The publisher reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
- The publisher analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
- The publisher reports source deal data from our proprietary deals and alliances database. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal.
- The data in the deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.
The publisher provides comprehensive coverage of the following partnering or deal types:
- Asset purchase
- Assignment
- Co-development
- Co-market
- Co-promotion
- Collaborative R&D
- Contract service
- CRADA
- Cross-licensing
- Development
- Distribution
- Equity purchase
- Evaluation
- Grant
- Joint venture
- Licensing
- Loan
- Manufacturing
- Marketing
- Option
- Promotion
- Research
- Royalty financing
- Settlement
- Spin out
- Sub license
- Supply
- Termination
- Warrant
Every deal record is fully categorized and includes the following data, where available:
- Industry sector
- Therapy areas
- Technology type
- Deal components
- Financial terms
- Stage of development
- Exclusivity
- Asset type
- Geographic focus
- Excluded geography
- Company press release
- SEC filing data including contract document
All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.
LOADING...
